Top Markets
Coin of the day
Alimera Sciences, Inc. Alimera Sciences, Inc.

Alimera Sciences, Inc.

ALIM
Pozycja w akcjach #26668
Alimera Sciences, Inc. is a pharmaceutical company focused on developing and... Alimera Sciences, Inc. is a pharmaceutical company focused on developing and commercializing ophthalmic treatments globally, including in the United States. Its primary offering, ILUVIEN, is an intravitreal implant used to manage diabetic macular edema (DME), a severe retinal disease in individuals with diabetes that can lead to profound vision loss and blindness. Additionally, ILUVIEN helps prevent relapses of recurrent non-infectious uveitis affecting the posterior segment of the eye. The company distributes its products directly and through distributors to various healthcare entities such as physician offices, pharmacies, and hospitals. Alimera also maintains a collaboration with EyePoint Pharmaceuticals US, Inc. focused on developing and marketing insert technology. This technology is designed to deliver corticosteroids to the back of the eye for treating and preventing various human eye diseases, including diabetic macular edema. Founded in 2003, Alimera Sciences is headquartered in Alpharetta, Georgia.
Cena akcji
$5.54
Ostatnia synchronizacja: 2024-09-18
Kapitalizacja rynkowa
$38.76M
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
0.00%
Kraj
US
Handel Alimera Sciences, Inc. (ALIM)

Kategoria

EPS dla Alimera Sciences, Inc. (ALIM)
EPS na dzień June 2024 TTM: $-0.28
Według najnowszych raportów finansowych i ceny akcji firmy Alimera Sciences, Inc., obecny EPS (TTM) wynosi $-0.28. Na koniec roku 2022 firma miała EPS w wysokości $-2.59, wzrost w porównaniu do do EPS z roku 2021, który wynosił $-0.66.
Historia EPS dla Alimera Sciences, Inc. od 2006 do 2026
EPS na koniec każdego roku
Rok EPS Zmień
2026 (TTM) $-0.28 -64.56%
2023 $-0.79 -69.50%
2022 $-2.59 292.42%
2021 $-0.66 -36.54%
2020 $-1.04 -52.51%
2019 $-2.19 -158.40%
2018 $3.75 -176.06%
2017 $-4.93 -47.66%
2016 $-9.42 -8.90%
2015 $-10.34 -22.43%
2014 $-13.33 -45.14%
2013 $-24.30 158.24%
2012 $-9.41 -12.63%
2011 $-10.77 61.95%
2010 $-6.65 -98.48%
2009 $-437.12 -23.24%
2008 $-569.46 977.30%
2007 $-52.86 -56.02%
2006 $-120.18 0.00%
EPS dla podobnych firm lub konkurentów